4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD

Reuters

Nov 20

Nov 6 (Reuters) - 4D Molecular Therapeutics Inc ::
*4DMT ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 1/2 PRISM CLINICAL TRIAL IN WET AMD SUPPORTING 4D-150’S POTENTIAL AS A BACKBONE THERAPY WITH CONSISTENT AND DURABLE BENEFIT OVER MULTIPLE YEARS
*4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO NEW SAFETY ISSUES

((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 06-NOV-202511:00:00.293 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2584692673"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584692673\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584692673?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 00:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584692673","market":"us","top_or_hot":-1,"title":"4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD","media":"Reuters","content":"<html><body>Nov 6 (Reuters) - <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> Inc <fdmt.o>::<br/>*4DMT ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 1/2 PRISM CLINICAL TRIAL IN WET <a href=\"https://laohu8.com/S/AMD\">AMD</a> SUPPORTING 4D-150’S POTENTIAL AS A BACKBONE THERAPY WITH CONSISTENT AND DURABLE BENEFIT OVER MULTIPLE YEARS<br/>*4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO NEW SAFETY ISSUES<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 06-NOV-202511:00:00.293 GMT</fdmt.o></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 00:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body>Nov 6 (Reuters) - <a href=\"https://laohu8.com/S/FDMT\">4D Molecular Therapeutics</a> Inc <fdmt.o>::<br/>*4DMT ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 1/2 PRISM CLINICAL TRIAL IN WET <a href=\"https://laohu8.com/S/AMD\">AMD</a> SUPPORTING 4D-150’S POTENTIAL AS A BACKBONE THERAPY WITH CONSISTENT AND DURABLE BENEFIT OVER MULTIPLE YEARS<br/>*4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO NEW SAFETY ISSUES<br/><br/>  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))<br/>  Source Date/Time = 06-NOV-202511:00:00.293 GMT</fdmt.o></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FDMT","symbol_name":"4D Molecular Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD3lx8jM:1","article_id":"2584692673","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584692673","pubTimestamp":1763571139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nov 6 (Reuters) - 4D Molecular Therapeutics Inc ::*4DMT ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 1/2 PRISM CLINICAL TRIAL IN WET AMD SUPPORTING 4D-150’S POTENTIAL AS A BACKBONE THERAPY WITH CONSIS","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FDMT":"4D Molecular Therapeutics","BK4139":"生物科技"},"translate_title":"4DMT报告长期1/2期数据显示4D-150在湿性AMD中具有持久的多年获益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FDMT":0.9},"content_text":"Nov 6 (Reuters) - 4D Molecular Therapeutics Inc ::*4DMT ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 1/2 PRISM CLINICAL TRIAL IN WET AMD SUPPORTING 4D-150’S POTENTIAL AS A BACKBONE THERAPY WITH CONSISTENT AND DURABLE BENEFIT OVER MULTIPLE YEARS*4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO NEW SAFETY ISSUES  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:00:00.293 GMT","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}